BUILDING A FOUNDATION:
Longer-Lasting “On” Time per Dose
In the past few decades, levodopa therapy has evolved to provide longer-lasting benefits for patients with Parkinson’s disease. The development of RYTARY has lead to reduced “off” time and more “on” time. In this article, Robert A. Hauser, MD, MBA, FAAN, and John C. Morgan, MD, PhD, review the results of a post hoc analysis on the duration of benefit per dose with RYTARY.
View More